Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Analyst Ratings
Strong Buy
16 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CYTK Stock 12 Month Forecast
Average Price Target
$81.00
▲(47.92% Upside)
| Highest Price Target$120.00 | Average Price Target$81.00 | Lowest Price Target$41.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$56→$62
Hold
13.22%
Upside
Reiterated
10/21/25
Cytokinetics' Aficamten Faces Competitive and Regulatory Challenges: Hold Rating MaintainedWe recognize afi may have distinct benefits, including a more flexible initiation, with its recent clinical wins another potential differentiator (see our ESC takes). That said, our KOLs continue to think price/ access is likely to be the main commercial driver. And with reasons to believe Bristol may have the upper hand negotiating formulary position—an edge it can leverage with its CV commercial experience, infrastructure, first mover status, and Camzyos’ own advantages—the space may be more competitive than initially thought. To review the different launch scenarios, we are hosting a prescriber (10/21 @ 9:30am ET) and a payer (10/22 @ 10am ET) call REMS still likely to be the biggest drag on launch, uptake In our view, FDA’s move to approve afi with a REMS (see our PDUFA takes) remains an overhang.
Cantor Fitzgerald
―
Buy
―
Reiterated
10/21/25
Barclays
$71→$82
Buy
49.74%
Upside
Reiterated
10/06/25
J.P. Morgan
―
Buy
―
Reiterated
09/30/25
Morgan Stanley
$65
Buy
18.70%
Upside
Reiterated
09/29/25
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for CytokineticsWe note that mavacamten in ODYSSEY-HCM, which failed to meet its dual primary endpoints (KCCQ-23 CSS and pVO2) at wk 48, showed least-squares mean change in the KCCQ-CSS of 13.1 points for mavacamten vs. 10.4 points for placebo (higher than expected vs. ~6 point placebo in Ph2 MAVERICK) for between-group difference of 2.7 points (P = 0.06) (see our note HERE). Aficamten also improved cardiac biomarkers, with both NT-proBNP and high-sensitivity cardiac troponin I rapidly declining by Week 12 and remaining low through Week 96 ( Exhibit 3 ). There was a modest reduction in left ventricular ejection fraction (LVEF) from hyperdynamic at baseline to within normal range at Week 12 (-6.2%; p<0.0001). Over the treatment period, four patients had LVEF <50% which were reversible after down titration or a short treatment interruption.
Stifel Nicolaus
$96→$95
Buy
73.48%
Upside
Reiterated
09/29/25
H.C. Wainwright
$120
Buy
119.14%
Upside
Reiterated
09/29/25
Cytokinetics' Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock OutlookValuation and potential impediments to achieving price target. We reiterate our Buy rating and $120 price target. Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate for capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.
B. Riley Securities
$74→$80
Buy
46.09%
Upside
Reiterated
09/22/25
RBC Capital
$80→$82
Buy
49.74%
Upside
Reiterated
09/08/25
Evercore ISI
$60→$80
Buy
46.09%
Upside
Reiterated
09/03/25
Citi
$77→$84
Buy
53.40%
Upside
Reiterated
09/03/25
Jefferies
$80
Buy
46.09%
Upside
Reiterated
09/03/25
Needham
$72
Buy
31.48%
Upside
Reiterated
09/02/25
Truist Financial
―
Buy
―
Reiterated
09/02/25
Leerink Partners
―
Buy
―
Reiterated
09/02/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$56→$62
Hold
13.22%
Upside
Reiterated
10/21/25
Cytokinetics' Aficamten Faces Competitive and Regulatory Challenges: Hold Rating MaintainedWe recognize afi may have distinct benefits, including a more flexible initiation, with its recent clinical wins another potential differentiator (see our ESC takes). That said, our KOLs continue to think price/ access is likely to be the main commercial driver. And with reasons to believe Bristol may have the upper hand negotiating formulary position—an edge it can leverage with its CV commercial experience, infrastructure, first mover status, and Camzyos’ own advantages—the space may be more competitive than initially thought. To review the different launch scenarios, we are hosting a prescriber (10/21 @ 9:30am ET) and a payer (10/22 @ 10am ET) call REMS still likely to be the biggest drag on launch, uptake In our view, FDA’s move to approve afi with a REMS (see our PDUFA takes) remains an overhang.
Cantor Fitzgerald
―
Buy
―
Reiterated
10/21/25
Barclays
$71→$82
Buy
49.74%
Upside
Reiterated
10/06/25
J.P. Morgan
―
Buy
―
Reiterated
09/30/25
Morgan Stanley
$65
Buy
18.70%
Upside
Reiterated
09/29/25
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for CytokineticsWe note that mavacamten in ODYSSEY-HCM, which failed to meet its dual primary endpoints (KCCQ-23 CSS and pVO2) at wk 48, showed least-squares mean change in the KCCQ-CSS of 13.1 points for mavacamten vs. 10.4 points for placebo (higher than expected vs. ~6 point placebo in Ph2 MAVERICK) for between-group difference of 2.7 points (P = 0.06) (see our note HERE). Aficamten also improved cardiac biomarkers, with both NT-proBNP and high-sensitivity cardiac troponin I rapidly declining by Week 12 and remaining low through Week 96 ( Exhibit 3 ). There was a modest reduction in left ventricular ejection fraction (LVEF) from hyperdynamic at baseline to within normal range at Week 12 (-6.2%; p<0.0001). Over the treatment period, four patients had LVEF <50% which were reversible after down titration or a short treatment interruption.
Stifel Nicolaus
$96→$95
Buy
73.48%
Upside
Reiterated
09/29/25
H.C. Wainwright
$120
Buy
119.14%
Upside
Reiterated
09/29/25
Cytokinetics' Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock OutlookValuation and potential impediments to achieving price target. We reiterate our Buy rating and $120 price target. Our price target is based on our clinical net present value (NPV) model. We believe this method is appropriate for capturing the value of the clinical stage pipeline by allowing us to flex multiple assumptions, including the chance of success, peak sales estimates, and year of commercial launch.
B. Riley Securities
$74→$80
Buy
46.09%
Upside
Reiterated
09/22/25
RBC Capital
$80→$82
Buy
49.74%
Upside
Reiterated
09/08/25
Evercore ISI
$60→$80
Buy
46.09%
Upside
Reiterated
09/03/25
Citi
$77→$84
Buy
53.40%
Upside
Reiterated
09/03/25
Jefferies
$80
Buy
46.09%
Upside
Reiterated
09/03/25
Needham
$72
Buy
31.48%
Upside
Reiterated
09/02/25
Truist Financial
―
Buy
―
Reiterated
09/02/25
Leerink Partners
―
Buy
―
Reiterated
09/02/25
Best Analysts Covering Cytokinetics
1 Month
xxx
Success Rate
13/18 ratings generated profit
Average Return
+17.02%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +17.02% per trade.
3 Months
xxx
Success Rate
10/18 ratings generated profit
Average Return
+28.10%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +28.10% per trade.
1 Year
Success Rate
36/51 ratings generated profit
Average Return
+32.81%
reiterated a buy rating 2 months ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +32.81% per trade.
2 Years
xxx
Success Rate
15/17 ratings generated profit
Average Return
+25.42%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +25.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CYTK Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
38
28
17
24
22
Buy
11
7
1
9
10
Hold
10
13
15
17
11
Sell
3
2
0
0
0
Strong Sell
0
0
0
0
0
total
62
50
33
50
43
Each month's total comprises the sum of three months' worth of ratings.
CYTK Financial Forecast
CYTK Stock Forecast FAQ
What is CYTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Cytokinetics’s 12-month average price target is 81.00.
What is CYTK’s upside potential, based on the analysts’ average price target?
Cytokinetics has 47.92% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CYTK a Buy, Sell or Hold?
Cytokinetics has a consensus rating of Strong Buy which is based on 16 buy ratings, 3 hold ratings and 0 sell ratings.
What is Cytokinetics’s price target?
The average price target for Cytokinetics is 81.00. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 47.92% Increase from the current price of $54.76.
The highest analyst price target is $120.00 ,the lowest forecast is $41.00. The average price target represents 47.92% Increase from the current price of $54.76.
What do analysts say about Cytokinetics?
Cytokinetics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of CYTK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.